PMC9807353_01
SCC arising from a SCT. (a) Clinical photograph showing an elevated lesion around the suprapubic cystostomy. (b) Tumor biopsy demonstrated a well-differentiated SCC. (c, d). Magnetic resonance images showing that the tumor involved the bladder wall along the site of the catheter.
IJU5-6-60-g003.jpg
PMC9807353_01_IJU5-6-60-g003.jpg
iju512554-fig-0001
A 61-year-old Japanese woman with paraplegia secondary to spina bifida and no history of cigarette smoking was referred to our hospital for investigation of a rapidly growing elevated lesion around a cystostomy site (Fig. 1a). Tumor biopsy confirmed well-differentiated SCC (Fig. 1b). Magnetic resonance imaging revealed a tumor along the catheter involving the bladder wall (Fig. 1c,d).
(a) Clinical photograph of the en bloc-resected specimen, including the skin lesion, muscle, suprapubic catheter, and urinary bladder. (b) Micrograph demonstrating well-differentiated SCC composed of well-defined intercellular bridges with keratinization in individual cells and keratin pearls.
IJU5-6-60-g002.jpg
PMC9807353_01_IJU5-6-60-g002.jpg
iju512554-fig-0002
Local excision with partial cystectomy was performed (Fig. 2a). Pathological examination confirmed SCC arising from SCT (Fig. 2b).
Results of IHC. The expression level of each biomarker was evaluated according to the staining intensity and proportion of positive cells in the total cell population. The antibodies used for the analyses were as follows: rabbit anti-VEGF polyclonal antibody (dilution 1:50, Zymed, South San Francisco, CA, USA), mouse anti-EGFR monoclonal antibody (ready to use, 2-18C9; Dako Corp, Carpinteria, CA, USA), mouse anti-COX-2 monoclonal antibody (dilution 1:100, CX-294, 1:100; Dako Corp), rabbit anti-Ki-67 monoclonal antibody (ready to use, SP6; Nichirei, Tokyo, Japan), mouse anti-p53 monoclonal antibody (dilution 1:50, DO-7; Dako Corp), mouse anti-p21 monoclonal antibody (dilution 1:50, SX118; Dako Corp), mouse anti-cyclin E monoclonal antibody (ready to use, ME12; Diagnostic BioSystems, Pleasanton, CA, USA), and mouse anti-Bcl-2 monoclonal antibody (dilution 1:100, clone 124; Dako Corp).
IJU5-6-60-g001.jpg
PMC9807353_01_IJU5-6-60-g001.jpg
iju512554-fig-0003
The antibodies used for the analyses are described in Figure 3. There were no Bcl-2-positive cells (Fig. 3).